Loading...
Market
Will orforglipron surpass Eli Lilly's injectables in popularity by end of 2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Sales reports and market analysis from Eli Lilly and industry reports
Story
Eli Lilly Anticipates Approval for Orforglipron Weight-Loss Pill in Early 2026
Jan 13, 2025, 06:07 PM
Eli Lilly & Co. is anticipating regulatory approval for its experimental weight-loss pill, orforglipron, as early as early 2026, according to CEO Dave Ricks. Ricks, speaking at the JPMorgan Healthcare Conference in San Francisco, indicated that data on the pill is expected by mid-2025. He highlighted that the oral form of the drug would be more convenient for patients and easier to manufacture at a large scale compared to the company's current injectable weight-loss drugs, which have faced supply shortages due to production constraints.
View original story
Similar markets
Yes • 50%
No • 50%
Approved in UK, EU, and USA • 25%
Approved in UK and EU • 25%
Approved in UK only • 25%
Not approved in any major market • 25%
Yes • 50%
No • 50%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Novo Nordisk • 25%
No • 50%
Yes • 50%
Other • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Novo Nordisk > 60% • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk 40-60% • 25%
